Prostate-Specific Antigen as a
Unique Routine Test in Monitoring
Therapy for Inoperable Prostate
Cancer: Comparison with
Radionuclide Bone Scan and
Prostatic Acid Phosphatase

Barichello, M.; Gion, Massimo; Bonazza, Adriano; Ponti, U. Santucci Delli; Bolgan, A.; Contemori, G. P.; Barioli, P.; Capitanio, Giovanni; Pecori, Biagio; Omacini, S.; Benvegnù, Luisa; Petracco, S.

doi:10.1159/000475184

Cited by 13 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main aim of the former study [9] was to assess the from 1 to 126 ng/mL (median 26); the medians of these two groups were significantly different (P<0.001).…”

Section: Methodsmentioning

confidence: 99%

“…In the PSA range of 10-20 ng/mL, Osterling et al [7] reported 98.6% of 385 bone scans, and Hucharek et al [8] 97.4% of 81 scans, were normal. The results from these larger studies are at variance The main aim of the former study [9] was to assess the from 1 to 126 ng/mL (median 26); the medians of these two groups were significantly different (P<0.001).…”

Section: Introductionmentioning

confidence: 99%

“…In total, 26 patients had a positive bone scan, their PSA values ranging from scans in 14 patients who had PSA levels of 10-20 ng/mL. It is unclear why these latter studies 43 to 18 600 ng/mL (median 1855), and 72 patients had a negative bone scan, with PSA values ranging show marked differences from the larger investigations.The main aim of the former study [9] was to assess the from 1 to 126 ng/mL (median 26); the medians of these two groups were significantly different (P<0.001).PSA response to treatment, and in the latter [10] there is no mention of equivocal scan findings, with all the Table 1 shows the trend between rising PSA levels and the proportion with positive bone scans (chi-square test bone scans apparently categorized as negative or positive. As these studies were retrospective, it is possible that for trend=45.3, P<0.001) and the predictive value of the PSA level for a normal bone scan.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Which patients with prostatic carcinoma require a staging bone scan

Kemp

Maguire

Bird

1997

British Journal of Urology

View full text Add to dashboard Cite

ObjectiveTo determine whether the level of prostateshowing bony metastases had a PSA level >40 ng/mL. Reviewing the other published studies specific antigen (PSA) can be used to decide which patients with newly diagnosed prostatic carcinoma showed that in those newly diagnosed patients with a PSA level of <20 ng/mL, the probability of having require a staging bone scan. Patients and methods Of patients referred during an bony metastases detected on a bone scan was <1%. Conclusions A staging bone scan can be omitted in the 18-month period for a staging bone scan, 98 (median age 72 years, range 52-89) had had their serum PSA vast majority of patients with newly diagnosed prostatic carcinoma and a PSA level <20 ng/mL. level determined within 4 weeks of the bone scan and were assessed retrospectively for the presence of bony Keywords Prostatic neoplasms, prostate-specific antigen, neoplasm staging, radionuclide imaging metastases.Results Of the 98 patients, 26 who had bone scans Introduction Patients and methodsThe notes of all patients referred for a bone scan from Prostatic carcinoma has the second highest cancer mortality in males in the UK. It is responsible for over 10 000 three consultant urologists over an 18 month period were scrutinized. Patients were included if there was (i) deaths and 14 000 new cases diagnosed each year. The difference in incidence and mortality reflect that some histological confirmation of the diagnosis of prostatic carcinoma, (ii) the staging bone scan and PSA level were men will die with, rather than from, prostatic carcinoma.It is common practice in the UK to undertake bone undertaken within 4 weeks of each other, (iii) the bone scan findings were unequivocal or equivocal findings scintigraphy as part of the routine staging procedure in men with newly diagnosed prostatic carcinoma. It has were confirmed by other imaging modalities and (iv) no therapy was initiated (surgery, radiotherapy or hormone been known for over 20 years that bone scintigraphy is more sensitive than whole-body skeletal radiography in manipulation) before the bone scan and PSA determination. detecting bony metastases [1]. However, although common practice, in recent years the necessity of scintigAll whole-body bone scans were carried out in the Department of Nuclear Medicine, Addenbrooke's NHS raphy for all cases has been questioned [2,3].PSA was first isolated in 1979 [4] and is derived from Trust and were acquired on an Elscint Helix APXSPX machine 4 h after an intravenous injection of 550 MBq acinar and ductal epithelial cells of normal, hyperplastic and carcinomatous prostatic tissue [5]. It is found in low of technetium-99 m MDP. Images were interpreted by consultants in Nuclear Medicine. Total PSA measureconcentrations in the serum of healthy men. Given that serum PSA is associated with increasing stage and ments were made in the Department of Biochemistry, Addenbrooke's NHS Trust using a two-site immunovolume of prostate cancer, it may be possible to use this serum marker to determine whether a bone sca...

show abstract

“…The main aim of the former study [9] was to assess the from 1 to 126 ng/mL (median 26); the medians of these two groups were significantly different (P<0.001).…”

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Which patients with prostatic carcinoma require a staging bone scan

Kemp

Maguire

Bird

1997

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…1,7,8 Prostatic-specific antigen is currently the best and most useful marker for prostate cancer. 9,10 However, it cannot accurately differentiate BPH from prostate neoplasm, because of a great deal of overlapping in PSA levels between BPH and prostate cancer, especially in the borderline cases (with PSA level between 4 and 10 ng/ml).…”

Section: Introductionmentioning

confidence: 99%

Evidence of a novel biomarker, αs1-Casein, a milk protein, in benign prostate hyperplasia

Wang

et al. 2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Benign prostate hyperplasia (BPH) is a common disease in elderly men. Although it is a nonmalignant disease, it has a significant detrimental impact on the quality of life in patients with latestage disease. Owing to the lack of specific markers, diagnosis of early-stage BPH has been proven unsuccessful. Recently, using two-dimensional electrophoresis, we identified a group of prostatic secretory proteins that are specifically produced by BPH cells (Xu et al., Electrophoresis 2003; 24: 1311). In this study, we investigated the potential diagnostic value of one of the secretory proteins, as1-Casein, in BPH by inmmunohistological staining of normal, BPH and prostate cancer tissues. We found that 90% (20 out of 22) of BPH tissues showed moderate to strong as1-Casein protein expression whereas none of the normal tissues (0 out of 10) and less than 10% of the prostate cancer tissues (3 out of 30) showed similar staining intensity. Our results suggest that as1-Casein may be a potential biomarker for early identification of BPH patients.

show abstract

“…The avalaible prostate markers, such as prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA), though useful in the detection of prostate cancer, are not specific for BPH [6][7][8]. For example, PSA is currently the best and most useful marker for prostate cancer [9,10].…”

Section: Introductionmentioning

confidence: 99%

Identification of a specifically expressed modified form of novel PSP‐94 protein in the secretion of benign prostatic hyperplasia

Wang

Ling

et al. 2003

Electrophoresis

View full text Add to dashboard Cite

Using two-dimensional gel electrophoresis, we investigated the profile of prostatic secretory proteins in human expressed prostatic secretion (EPS) from benign prostate hyperplasia (BPH) patients and compared the patterns with normal controls. We identified three specifically expressed proteins, including prostate secretory protein 61 (PSP61), in EPS from benign BPH patients but absent in normal controls. In addition, we found that PSP61 was a modified isoform of the well-documented PSP-94, which had a perfect matching (100% homology) to the first 61 amino acids of the PSP-94 protein but with a deleted C-terminus. This shortened PSP61 was not due to alternative splicing of the PSP-94 gene at transcription level. Our results provide first evidence on the possibility of using PSP61 as a specific biological marker for diagnosis of BPH.

show abstract

Prostate-Specific Antigen as a Unique Routine Test in Monitoring Therapy for Inoperable Prostate Cancer: Comparison with Radionuclide Bone Scan and Prostatic Acid Phosphatase

Cited by 13 publications

References 15 publications

Which patients with prostatic carcinoma require a staging bone scan

Which patients with prostatic carcinoma require a staging bone scan

Evidence of a novel biomarker, αs1-Casein, a milk protein, in benign prostate hyperplasia

Identification of a specifically expressed modified form of novel PSP‐94 protein in the secretion of benign prostatic hyperplasia

Contact Info

Product

Resources

About